temoporfin has been researched along with Cholangiocarcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZL; Gadoora, MA; Gao, YH; Li, MY; Meharban, F; Nyokong, T; Sajjad, F; Wang, JH; Yan, YJ | 1 |
| Fabian, J; Herrmann, FC; Langer, K; Mulac, D; Stein, NC | 1 |
| Betz, CS; Göke, B; Kniebühler, G; Pongratz, T; Schirra, J; Sroka, R; Stepp, H | 1 |
| Ortner, MA | 1 |
1 review(s) available for temoporfin and Cholangiocarcinoma
| Article | Year |
|---|---|
Photodynamic therapy for cholangiocarcinoma: overview and new developments.
Topics: Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Hematoporphyrins; Humans; Interleukin-6; Mesoporphyrins; Neovascularization, Pathologic; Photochemotherapy; Photosensitizing Agents; Stents | 2009 |
1 trial(s) available for temoporfin and Cholangiocarcinoma
| Article | Year |
|---|---|
Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)).
Topics: Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Mesoporphyrins; Middle Aged; Photochemotherapy; Photosensitizing Agents; Stents; Survival Rate; Treatment Outcome | 2013 |
2 other study(ies) available for temoporfin and Cholangiocarcinoma
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Female; Humans; Light; Male; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Necrosis; Photochemotherapy; Photosensitizing Agents; Porphyrins; Xenograft Model Antitumor Assays | 2020 |
Nanoparticle albumin-bound mTHPC for photodynamic therapy: Preparation and comprehensive characterization of a promising drug delivery system.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Mesoporphyrins; Nanoparticles; Photochemotherapy; Photosensitizing Agents; Serum Albumin, Bovine; Solubility | 2020 |